Artivion delivered an exceptionally strong second quarter in 2025, achieving $113.0 million in revenue, a 15% increase year-over-year. The company reported a net income of $1.3 million and a non-GAAP net income of $10.7 million. Adjusted EBITDA saw a substantial 33% increase to $24.8 million, demonstrating the company's ability to scale and expand margins. Key drivers for revenue growth included On-X and stent grafts, both growing over 20% on a constant currency basis.

Artivion, Inc. reported a 2% increase in total revenues to $99.0 million for the first quarter of 2025 compared to the same period last year, driven by growth in stent grafts, On-X, and BioGlue, despite a net loss of $(0.5) million.

Artivion reported a 4% increase in revenue on a GAAP basis for Q4 2024, reaching $97.3 million, and a 10% increase for the full year 2024, reaching $388.5 million. The company achieved positive free cash flow and significant growth in adjusted EBITDA, while also making strides in clinical and regulatory initiatives, including receiving Humanitarian Device Exemption for AMDS.

Artivion reported a 9% increase in revenue compared to Q3 2023, driven by growth in key product lines and geographic regions. The company achieved several R&D milestones, including regulatory approval for BioGlue in China and submission of the first module of the PMA application for AMDS with the FDA. The company is narrowing its revenue guidance and continues to expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023 and now expects a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million.

Artivion reported a 10% increase in revenue for the second quarter of 2024, driven by growth in On-X and stent grafts, as well as strong performance in Latin America and Asia Pacific. The company raised its full year revenue and adjusted EBITDA guidance.

Artivion reported a strong first quarter in 2024, with a 17% increase in revenue, reaching $97.4 million. The company achieved a net income of $7.5 million, or $0.18 per share, and a non-GAAP net income of $2.6 million, or $0.06 per share. Due to this strong performance, Artivion raised the lower end of its full-year revenue guidance.

Artivion's fourth-quarter revenue increased by 18% on a GAAP basis and 15% on a non-GAAP constant currency basis, reaching $93.7 million. The company's non-GAAP net income was $4.6 million, or $0.11 per fully diluted share. The revenue growth was strong across all four product lines and geographies, with On-X and tissue processing showing particularly strong performance.

Artivion reported a 14% increase in revenue to $87.9 million in Q3 2023. Net loss decreased to ($9.8) million, and non-GAAP net income was $749,000. The company is raising its revenue guidance for the full year 2023.

Artivion reported an 11% increase in revenue to $89.3 million for the second quarter of 2023. The company's non-GAAP net income was $2.3 million, or $0.06 per share, compared to a non-GAAP net loss of ($1.3) million, or ($0.03) per share for the second quarter of 2022. The company is raising its revenue guidance range and now expects to achieve constant currency revenue growth of between 10% and 12% for the full year 2023 compared to 2022.

Artivion reported strong first quarter results with a constant currency revenue growth of 10% year-over-year. The company is on track to achieve or exceed the revenue and EBITDA growth targets for 2023 and beyond. They also received an Approvable Letter from the FDA for the PerClot PMA and expects approval after the report for their recent pre-approval inspection is finalized.

Artivion, Inc. reported flat revenue of $79.4 million for the fourth quarter of 2022 compared to the fourth quarter of 2021. Net income for the fourth quarter of 2022 was $2.2 million, or $0.05 per fully diluted common share, compared to net loss of ($20.1) million, or ($0.51) per fully diluted common share for the fourth quarter of 2021.

Artivion reported a 6% increase in revenue on a GAAP basis and an 11% increase on a non-GAAP constant currency basis compared to the third quarter of 2021. The company experienced growth across all major product lines and made progress in advancing its product pipeline.

Artivion reported a revenue of $80.3 million, a 6% increase compared to the second quarter of 2021. The company's net loss was ($4.3) million, or ($0.11) per fully diluted common share.

Artivion reported an 8.6% increase in revenue compared to Q1 2021, reaching $77.2 million. The company's growth was driven by a 34% increase in aortic stent grafts and an 11% increase in On-X sales. The company continues to expect to receive FDA PMA approval for PROACT Mitral and for PerClot this year.

Artivion reported record quarterly revenues of $79.4 million, driven by aortic stent grafts and strength in the US On-X aortic valve business. The company's net loss was $20.1 million, or $0.51 per share, while non-GAAP net loss was $0.141 million, or $0.00 per share. Artivion is progressing with regulatory approvals and expects continued growth, reflected in their positive financial outlook.

CryoLife reported an 11% increase in total revenues compared to Q3 2020, driven by recent product launches and strength in the U.S. On-X aortic valve business. Net income was $10.6 million, or $0.26 per share, compared to a net loss of ($2.9) million, or ($0.08) per share for the third quarter of 2020.

CryoLife reported a strong second quarter with a 42% increase in revenue compared to the previous year. The company saw growth driven by new product launches, normalization of procedure volumes, and strength in the U.S. On-X business. They are on track to file PMAs for PerClot and PROACT Mitral in the third quarter.

CryoLife reported a 7% increase in total revenues compared to Q1 2020. The company's growth was driven by new product launches outside the U.S., a recovery in procedure volume in the U.S., an improved JOTEC inventory position, and international expansion efforts.

CryoLife reported Q4 2020 financial results with total revenues of $67.9 million, a net loss of $(3.5) million, or $(0.09) per share, and a non-GAAP net income of $7.9 million, or $0.20 per share.

CryoLife reported a decrease in total revenues by 4% compared to the third quarter of 2019. The company achieved a net loss of $2.9 million, or $0.08 per share, but a non-GAAP net income of $4.9 million, or $0.13 per share. CryoLife also completed the acquisition of Ascyrus Medical LLC.

CryoLife reported a decrease in total revenues by 24% to $53.8 million compared to the second quarter of 2019. The company experienced a net loss of $3.7 million, or $0.10 per share, compared to a net income of $2.8 million, or $0.07 per share, in the same period last year. Despite the challenges, CryoLife is optimistic about continued momentum in the second half of 2020 and a strong 2021.

CryoLife reported a decrease in total revenues by 2% to $66.4 million for the first quarter of 2020. The company experienced a net loss of $6.7 million, or $0.18 per share, compared to a net loss of $0.3 million, or $0.01 per share, in the first quarter of 2019. Growth in tissue processing and On-X revenues was offset by decreases in BioGlue and JOTEC revenues.

CryoLife reported a 3% increase in total revenues for Q4 2019, reaching $69.7 million. The company's net loss was ($681,000), or ($0.02) per share, while non-GAAP net income was $3.8 million, or $0.10 per share.